Regulation of cell proliferation and apoptosis by bioactive lipid mediators

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 3, 2006, Pages 369-382

  Clària, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Apoptosis; Cell proliferation; Leukotrienes; Lipoxins; Lysophospholipids; Prostaglandins

Indexed keywords

ARACHIDONIC ACID; LIPID; LIPOXIN; LIPOXYGENASE; LYSOPHOSPHOLIPID; PROSTAGLANDIN SYNTHASE;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECT; ENZYMOLOGY; HUMAN; LIPID METABOLISM; METABOLISM; NEOPLASM; PATENT; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; ARACHIDONIC ACID; CELL PROLIFERATION; HUMANS; LIPID METABOLISM; LIPIDS; LIPOXINS; LIPOXYGENASE; LYSOPHOSPHOLIPIDS; NEOPLASMS; PATENTS AS TOPIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SIGNAL TRANSDUCTION;

EID: 39049094254     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206778776961     Document Type: Review

References (199)

1. Rosenthal MD, Rzigalinski BA, Blackmore PF, Franson RC. Cellular regulation of arachidonate mobilization and metabolism. Prostaglandins Leukotrienes Essent Fatty Acids 1995; 52: 93-98.
2. Balsinde J, Winstead MV, Dennis EA. Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett 2002; 531: 2-6.
3. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-75.
4. Romano M, Clària J. Cyclooxygenase-2 and 5-Lipoxygenase converging functions on cell proliferation and tumor angiogenesis: Implications for cancer therapy. FASEB J 2003; 17: 1986-95.
5. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-76.
6. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukotrienes Essent Fatty Acids 2005; 73: 163-77.
7. Ohki S, Ogino N, Yamamoto S, Hayaishi O. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1979; 254: 829-36.
8. Smith WL, Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and-2. Prostaglandins Other Lipid Mediators 2002: 68-69; 115-28.
9. Dudzinski DM, Serhan CN. Pharmacology of eicosanoids. In: Golan DE, Tashjian AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS, Eds. Principles of Pharmacology. The pathophysiologic basis of drug therapy. Philadelphia, PA, Lippincott Williams & Wilkins 2004; 627-46.
10. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999; 96: 7220-25.
11. 2 biosynthesis. J Biol Chem 2000; 275: 32775-82.
12. Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res 2004; 43: 3-35.
13. Tanikawa N, Ohmiya Y, Ohkubo H, et al. Identification and characterization of a novel type of membrane-associated prostaglan-din E synthase. Biochem Biophys Res Commun 2002; 291: 884-89.
14. Mancini JA, Blood K, Guay J, et al. Cloning, expression, and upregulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J Biol Chem 2001; 276: 4469-75.
15. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-90.
16. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-61.
17. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-72.
18. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-96.
19. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266: 23261-67.
20. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54.
21. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediators 2002; 68-69: 95-114.
22. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-88.
23. Clària J. Cyclooxygenase-2 biology. Curr Pharm Des 2003; 9: 2177-90.
24. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta Lipids Lipid Metab 1996; 1299: 125-40.
25. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediators 2002; 68-69: 165-75.
26. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-23.
27. Rao CV, Simi B, Wynn TT, Garr K, Reddy BS. Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res 1996; 56: 532-37.
28. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-88.
29. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816-20.
30. Dubois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110: 1259-62.
31. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111: 1134-40.
32. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
33. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
34. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999; 18: 305-14.
35. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001; 98: 6905-10.
36. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc i716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-09.
37. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
38. Rigau J, Piqué JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952-54.
39. Young, D.A., O'Banion, M.K., Winn, V.D.: US20006048850 (2000).
40. Young, D.A., O'Banion, M.K., Winn, V.D.: US5837479 (1998).
41. Fujimoto, R.A., McQuire, L.W., Mugrage, B.B., Van Duzer, J.H.: US20046727281 (2004).
42. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
43. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733-40.
44. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999; 91: 1501-04.
45. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62: 5778-84.
46. Han JA, Kim JI, Ongusaha PP, et al. P53-mediated induction of Cox-2 counteracts p53-or genotoxic stress-induced apoptosis. EMBO J 2002; 21: 5635-44.
47. Karin, M., Kapahi, P.: US20036649654 (2003).
48. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254-59.
49. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12.
50. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997; 3: 1679-83.
51. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997; 57: 2452-59.
52. Monneret G, Cossette C, Gravel S, Rokach J, Powell WS. 15Rmethyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils. J Pharmacol Exp Ther 2003; 304: 349-55.
53. Chawla A, Repa JJ, Evans RM, Mangeldsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001; 294: 1866-70.
54. Forman BM, Tontonoz P, Chen J, Brun RP, Speigelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-12.
55. Petrova TV, Akama KT, Van Eldik LJ. Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc Natl Acad Sci USA 1999; 96: 4668-73.
56. Thieringer R, Fenyk-Melody JE, Le Grand CB, et al. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 2000; 164: 1046-54.
57. Tsubouchi Y, Kawahito Y, Kohno M, Inoue K, Hla T, Sano H. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12,14)-prostaglandin J2. Biochem Biophys Res Commun 2001; 283: 750-55.
58. Quraishi O, Mancini JA, Riendeau D. Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglan-din J(2) and polyunsaturated fatty acids. Biochem Pharmacol 2002; 63: 1183-89.
59. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3: 401-16.
60. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001; 21: 185-210.
61. Clay CE, Namen AM, Atsumi G, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999; 20: 1905-11.
62. Wilmer WA, Dixon C, Lu L, Hilbelink T, Rovin BH. A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARgamma. Biochem Biophys Res Commun 2001; 16; 281: 57-62.
63. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 1999; 274: 17042-48.
64. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats J Clin Invest 2000; 106: 189-197.
65. Planagumà A, Clària J, Miquel R, et al. Inhibition of COX-2 reduces liver fibrosis by mechanisms involving kupffer cell apoptosis and PPARaaactivation. FASEB J 2005; 19: 1120-1122.
66. Gilroy DW, Colville-Nash PR, McMaster S, et al. Inducible cyclooxygenase-derived 15-deoxy(Delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J 2003; 17: 2269-71.
67. Ward C, Dransfield I, Murray J, Farrow SN, Haslett C, Rossi AG. Prostaglandin D2 and its metabolites induce caspasedependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferatoractivated receptor-gamma-independent mechanism. J Immunol 2002; 168: 6232-43.
68. Li L, Tao J, Davaille J, et al. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisomeproliferator-activated receptors. J Biol Chem 2001; 276: 38152-58.
69. Emi M, Maeyama K. The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. Biochem Pharmacol 2004; 67: 1259-67.
70. Kondo M, Shibata T, Kumagai T, et al. 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci USA 2002; 99: 7367-72.
71. Santoro, M.G., Rossi, A., Elia, G.: US20046696498 (2004).
72. Funk CD, Funk LB, FitzGerald GA, Samuelsson B. Characterization of human 12-lipoxygenase genes. Proc Natl Acad Sci USA 1992; 89: 3962-66.
73. Radmark O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediators 2002; 68-69: 211.
74. Funk CD, Hoshiko S, Matsumoto T, Radmark O, Samuelsson B. Characterization of the human 5-lipoxygenase gene. Proc Natl Acad Sci USA 1989: 86: 2587-91.
75. Hoshiko S, Radmark O, Samuelsson B. Characterization of the human 5-lipoxygenase gene promoter. Proc Natl Acad Sci USA 1990; 87: 9073-77.
76. Pouliot M, McDonald PP, Krump E, et al. Colocalization of cytosolic phospholipase A2, 5-lipoxygenase, and 5-lipoxygenase-activating protein at the nuclear membrane of A23187-stimulated human neutrophils. Eur J Biochem 1996; 238: 250-58.
77. Borgeat P, Hamberg M, Samuelsson B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J Biol Chem 1976; 251: 7816-20.
78. Dixon RAF, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343: 282-84.
79. Rouzer CA, Matsumoto T, Samuelsson B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc Natl Acad Sci USA 1986; 83: 857-61.
80. 4 hydrolase in human leukocytes. Purification and properties. J Biol Chem 1984; 259: 12339-45.
81. 4 synthase. A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes. Am J Respir Crit Care Med 2000; 161: S16-9.1.
82. 4 that mediates chemotaxis. Nature 1997; 387: 620-24.
83. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192: 421-32.
84. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399: 789-93.
85. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531-36.
86. Powell WS, Rokach J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res 2005; 44: 154-83.
87. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999; 59: 2223-2228.
88. Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001; 15: 2007-2009.
89. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest1996; 97: 806-813.
90. Kargman S, Vickers PJ, Evans JF. A23187 induces translocation of 5-lipoxygenase in osteosarcoma cells. J Cell Biol 1992; 119: 1701-1709.
91. Boado RJ, Pardridge WM, Vinters HV, Black, KL. Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. Proc Natl Acad Sci USA 1992; 89: 9044-9048.
92. Hennig R, Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol 2002; 161: 421-28.
93. Romano M, Catalano A, Nutini M, et al. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15: 2326-36.
94. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001; 91, 737-43
95. 1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003; 124: 57-70.
96. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000; 161: 1881-86.
97. Walker JL, Loscalzo J, Zhang YY. 5-Lipoxygenase and human pulmonary artery endothelial cell proliferation. Am J Physiol 2002; 282: 585-93.
98. Uz T, Manev R, Manev H. 5-Lipoxygenase is required for proliferation of immature cerebellar granule neurons in vitro. Eur J Pharmacol 2001; 418: 15-22.
99. Ou D, Bonomi P, Jao W, Jadko S, Harris JE, Anderson KM. The mode of cell death in H-358 lung cancer cells cultured with inhibitors of 5-lipoxygenase or the free radical spin trap, NTBN. Cancer Lett 2001; 166: 223-31.
100. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 13182-87.
101. Anderson KM, Seed T, Meng J, Ou D, Alrefai WA, Harris JE. Five-lipoxygenase inhibitors reduce Panc-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid. Anticancer Res 1998; 18: 791-800.
102. Tsukada T, Nakashima K, Shirakawa S. Arachidonate 5-lipoxygenase inhibitors show potent antiproliferative effects on human leukemia cell lines. Biochem Biophys Res Commun 1986; 140: 832-36.
103. Titos E, Clària J, Planagumà A, et al. Inhibition of 5-Lipoxygenase Induces Cell Growth Arrest and Apoptosis in Rat Kupffer Cells. Implications in liver fibrosis. FASEB J 2003; 17: 1745-47.
104. Catalano A, Caprari P, Soddu S, Procopio A, Romano M. 5-Lipoxygenase antagonizes p53-induced apoptosis of cancer cells by altering p53 nuclear trafficking. FASEB J 2004; 18: 1740-42.
105. Anderson, J., Matsui, M.S.: US20016248341 (2001).
106. Baud L, Sraer J, Perez J, Nivez MP, Ardaillou R. Leukotriene C4 binds to human glomerular epithelial cells and promotes their proliferation in vitro. J Clin Invest 1985; 76: 374-77
107. Baud L, Perez J, Denis M, Ardaillou R. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J Immunol 1987; 138: 1190-95.
108. Yamaoka KA, Claesson HE, Rosen A. Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. J Immunol 1989; 143: 1996-2000.
109. Leikauf GD, Claesson HE, Doupnik CA, Hybbinette A, Grafstrom RC. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am J Physiol 1990; 259: L255-61.
110. Palmberg L, Lindgren JA, Thyberg J, Claesson HE. On the mechanism of induction of DNA synthesis in cultured arterial smooth muscle cells by leukotrienes. Possible role of prostaglandin endoperoxide synthase products and plateletderived growth factor. J Cell Sci 1991; 98: 141-49.
111. Kragballe K, Desjarlais L, Voohees JJ. Leukotrienes B4, C4 and D4 stimulate DNA synthesis in cultured human epidermal keratinocytes. Br J Dermatol 1985; 113: 43-52.
112. Moretti RM, Montagnani Marelli M, Sala A, Motta M, Limonta P. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int J Cancer 2004; 112: 87-93.
113. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997; 235: 418-23.
114. Provost P, Samuelsson B, Radmark O. Interaction of 5-lipoxygenase with cellular proteins. Proc Natl Acad Sci USA 1999; 96: 1881-85.
115. Lepley RA, Fitzpatrick FA. 5-Lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. J Biol Chem 1994; 269: 24163-68.
116. Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000; 97: 11280-85.
117. Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 1996; 93: 5241-46.
118. Datta K, Biswal SS, Kehrer JP. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J 1999; 340: 371-75.
119. Yamamoto S, Suzuki H, Ueda N. Arachidonate 12-lipoxygenases. Prog Lipid Res 1997; 36: 23-41.
120. Yoshimoto T, Takahashi Y. Arachidonate 12-lipoxygenases. Prostaglandins Other Lipid Mediat 2002; 68-69: 245-62.
121. Funk CD, Furci L, FitzGerald GA. Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc Natl Acad Sci USA 1990; 87: 5638-42.
122. Watanabe T, Medina JF, Haeggstrom JZ, Radmark O, Samuelsson B. Molecular cloning of a 12-lipoxygenase cDNA from rat brain. Eur J Biochem 1993; 212: 605-12.
123. De Marzo N, Sloane DL, Dicharry S, Highland E, Sigal E. Cloning and expression of an airway epithelial 12-lipoxygenase. Am J Physiol 1992; 262: L198.
124. Nie D, Honn KV. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 2002; 59: 799-807.
125. Nie D, Che M, Grignon D, Tang K, Honn KV. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev 2001; 20: 195-206.
126. Natarajan R, Esworthy R, Bai W, Gu JL, Wilczynski S, Nadler J. Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. J Clin Endocrinol Metab 1997; 82: 1790-98.
127. Krieg P, Kinzig A, Ress-Loschke M, et al. 12-Lipoxygenase isoenzymes in mouse skin tumor development. Mol Carcinog 1995; 14: 118-29.
128. Chen YQ, Duniec ZM, Liu B, et al. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res 1994; 54: 1574-79.
129. Steele VE, Holmes CA, Hawk ET, et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999; 8: 467-83.
130. Liu XH, Connolly JM, Rose DP. The 12-lipoxygenase genetransfected MCF-7 human breast cancer cell line exhibits estrogen-independent, but estrogen and omega-6 fatty acidstimulated proliferation in vitro, and enhanced growth in athymic nude mice. Cancer Lett 1996; 109: 223-30.
131. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999; 274: 23679-82.
132. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15Slipoxygenase in humans. Proc Natl Acad Sci USA 1997; 94: 6148-52.
133. Kelavkar UP, Cohen C, Kamitani H, Eling TE, Badr KF. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 2000; 21: 1777-87.
134. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 1999; 155: 235-45.
135. His LC, Wilson LC, Eling TE. Opposing Effects of 15-Lipoxygenase-1 and-2 Metabolites on MAPK Signaling in Prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 2002; 277: 40549-56.
136. Shappell SB, Gupta RA, Manning S, et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61: 497-503.
137. Marcus AJ. Transcellular metabolism of eicosanoids. Prog Hemost Thromb 1986; 8: 127-42.
138. Serhan CN, Sheppard KA. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 1990; 85: 772-80.
139. Serhan CN, Romano M. Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. J Lipid Mediat Cell Signal 1995; 12: 293-306.
140. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984; 81: 5335-39.
141. Clària J, Lee MH, Serhan CN. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996; 2: 583-96.
142. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2: 612-19.
143. Bannenberg GL, Chiang N, Ariel A, et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005; 174: 4345-55.
144. Chavis C Vachier I, Chanez P, Bousquet J, Godard P. 5(S),15 (S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. J Exp Med 1996; 183: 1633-43.
145. Clària J, Titos E, Jiménez W, et al. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with liver cirrhosis. Gastroenterology 1998; 115: 147-156.
146. Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995; 92: 9475-79.
147. Serhan, C.N., Clish, C.B.: US20036670396 (2003).
148. Lee TH, Horton CE, Kyan-Aung U, Haskard D, Crea AE, Spur BW. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin Sci 1989; 77: 195-203.
149. Colgan SP, Serhan CN, Parkos CA, Delp-Archer C, Madara JL. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 1993; 92: 75-82.
150. Papayianni A, Serhan CN, Brady HR. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 1996; 56: 2264-72.
151. Gronert K, Gewirtz A, Madara JL, Serhan CN. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med 1998; 187: 1285-94.
152. Hachicha M, Pouliot M, Petasis NA, Serhan CN. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 1999; 189: 1923-30.
153. 4. FASEB J 2002; 16: 1937-1939.
154. Scalia R, Gefen J, Petasis NA, Serhan CN, Lefer AM. Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc Natl Acad Sci USA 1997; 94: 9967-72.
155. Takano T, Clish CB, Gronert K, Petasis NA, Serhan CN. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epilipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest 1998; 101: 819-26.
156. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med 1997; 185: 693-704.
157. Kieran NE, Maderna P, Godson C. Lipoxins: potential antiinflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int 2004; 65: 1145-54.
158. Pouliot M, Clish CB, Petasis NA, Van Dyke TE, Serhan CN. Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 2000; 39: 4761-68.
159. Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003; 82: 82-90.
160. Chiang N, Gronert K, Clish CB, O'Brien JA, Freeman MW, Serhan CN. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999; 104: 309-16.
161. Levy BD, De Sanctis GT, Devchand PR, et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nature Med 2002; 8: 1018-23.
162. Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5: 388-92.
163. Fiorucci S, Wallace JL, Mencarelli A, et al. A beta-oxidationresistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci USA 2004; 101: 15736-41.
164. Fierro IM, Kutok JL, Serhan CN. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 2002; 300: 385-92.
165. Fierro IM. Angiogenesis and lipoxins. Prostaglandins Leukotrienes Essent Fatty Acids 2005; 73: 271-75.
166. McMahon B, Stenson C, McPhillips F, Fanning A, Brady HR, Godson C. Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem 2000; 275: 27566-75.
167. Mitchell D, Rodgers K, Hanly J, et al. Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am J Pathol 2004; 164: 937-46.
168. McMahon B, Mitchell D, Shattock R, Martin F, Brady HR, Godson C. Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J 2002; 16: 1817-19.
169. Cezar-de-Mello PF, Nascimiento-Silva V, Villela CG, Fierro IM. Aspirin-triggered Lipoxin A(4) inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 2005; doi: 10.1038/sj. onc.1209002.
170. Serhan, C.N., Fierro, I.M.: US20036627658 (2003).
171. Wu SH, Lu C, Dong L, Zhou GP, He ZG, Chen ZQ. High dose of lipoxin A4 induces apoptosis in rat renal interstitial fibroblasts. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 127-37.
172. Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA 2002; 99: 13266-71.
173. Sodin-Semrl S, Tadeo B, Tseng D, Varga J, Fiore S. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 2000; 164: 2660-66.
174. Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediators 2004; 73: 155-72.
175. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids. Receptor Revelations. Science 2001; 294: 1875-1878.
176. Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 1998; 12: 1589-98.
177. Fourcade O, Simon MF, Viode C, et al. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 1995; 80: 919-27.
178. Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem 2004; 92: 882-99.
179. Tokumura A. A family of phospholipid autacoids: occurrence, metabolism and bioactions. Prog Lipid Res 1995; 34: 151-84.
180. Small, C.L., Parrott, J.A., Zhong-Xu, L.: US20016248553 (2001).
181. Small, C.L., Parrott, J.A., Zhong-Xu, L.: US20016255063 (2001).
182. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004; 26: 870-81.
183. Wang A, Deems RA, Dennis EA. Cloning, expression, and catalytic mechanism of murine lysophospholipase I. J Biol Chem 1997; 272: 12723-29.
184. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005; 5: 560-70.
185. Spiegel, S., Kohama, T.: US20046800470 (2004).
186. Goetzl EJ, Rosen H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J Clin Invest 2004; 114: 1531-37.
187. Erickson, J.R.: US20026380177 (2002).
188. Ghosh S, Strum JC, Bell RM. Lipid biochemistry: functions of glycerolipids and sphingolipids in cellular signaling. FASEB J 1997; 11: 45-50.
189. Van Brocklyn JR, Young N, Roof R. Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett 2003; 199: 53-60.
190. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 2002; 281: 115-27.
191. Payne SG, Milstien S, Spiegel S. Sphingosine-1-phosphate: dual messenger functions. FEBS Lett 2002; 531: 54-57.
192. Morales-Ruiz M, lee MJ, Zollner S, et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem 2001; 276: 19672-77.
193. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4: 604-16.
194. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T. Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med 2001; 31: 717-28.
195. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001; 15: 719-30.
196. Umezu-Goyo M, Tanyi J, Lahad J, et al. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem 2004; 92: 1115-40.
197. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-23.
198. Riboni L, Campanella R, Bassi R, et al. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002; 39: 105-13.
199. Rylova SN, Somova OG, Dyatlovitskaya EV. Comparative investigation of sphingoid bases and fatty acids in ceramides and sphingomyelins from human ovarian malignant tumors and normal ovary. Biochemistry 1998; 63: 1057-60.